Conditioned medium from human palatine tonsil mesenchymal stem cells attenuates acute graft‑vs.‑host disease in mice

Cho,Kyung‑Ah; Kim,Yu‑Hee; Park,Minhwa; Kim,Hye Ji; Woo,So‑Youn; Park,Joo‑Won; Ryu,Kyung‑Ha

doi:10.3892/mmr.2018.9659

Conditioned medium from human palatine tonsil mesenchymal stem cells attenuates acute graft‑vs.‑host disease in mice

Authors:
- Kyung‑Ah Cho
- Yu‑Hee Kim
- Minhwa Park
- Hye Ji Kim
- So‑Youn Woo
- Joo‑Won Park
- Kyung‑Ha Ryu
View Affiliations

Affiliations: Department of Microbiology, College of Medicine, Ewha Womans University, Seoul 07985, Republic of Korea, Department of Biochemistry, College of Medicine, Ewha Womans University, Seoul 07985, Republic of Korea, Department of Pediatrics, College of Medicine, Ewha Womans University, Seoul 07985, Republic of Korea
Published online on: November 13, 2018 https://doi.org/10.3892/mmr.2018.9659
Pages: 609-616

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Graft-vs.-host disease (GVHD) is a severe and potentially life-threatening complication of hematopoietic stem cell transplantation. Approximately 50% of patients exhibiting GVHD will not benefit from conventional steroid treatment. Although several second‑line treatments are available for these patients, their prognoses remain poor due to the increased risk of infection, immunosuppression-mediated toxicity and incomplete GVHD remission, which occurs in the majority of cases. Mesenchymal stem cells (MSCs), a multipotent cell population, possess broad immunosuppressive activity and are a reportedly effective treatment of GVHD. However, the therapeutic effects of conditioned medium from MSCs on GVHD have not been demonstrated. In the present study, the efficacy of conditioned medium from human palatine tonsil‑derived MSCs (T‑MSC‑CM) was validated against GVHD in mice. The suppressive function of T‑MSC‑CM on immune cell chemotaxis was confirmed in vitro. A systemic infusion of T‑MSC‑CM in mice with GVHD resulted in prolonged survival, rapid recovery from weight loss and reduced pathological damage in numerous GVHD‑targeted organs. Furthermore, lymphocyte gene expression was significantly downregulated in GVHD mice administered T‑MSC‑CM. These results indicate that T‑MSC‑CM is a promising cellular agent to prevent or treat transplantation‑associated complications such as GVHD.

View Figures

View References

1	Ferrara JL, Levine JE, Reddy P and Holler E: Graft-versus-host disease. Lancet. 373:1550–1561. 2009. View Article : Google Scholar : PubMed/NCBI
2	Bacigalupo A: Management of acute graft-versus-host disease. Br J Haematol. 137:87–98. 2007. View Article : Google Scholar : PubMed/NCBI
3	MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK, Davies SM and Blazar BR: Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. Biol Blood Marrow Transplant. 8:387–394. 2002. View Article : Google Scholar : PubMed/NCBI
4	Deeg HJ: How I treat refractory acute GVHD. Blood. 109:4119–4126. 2007. View Article : Google Scholar : PubMed/NCBI
5	Perez L, Anasetti C and Pidala J: Have we improved in preventing and treating acute graft-versus-host disease? Curr Opin Hematol. 18:408–413. 2011. View Article : Google Scholar : PubMed/NCBI
6	Garnett C, Apperley JF and Pavlů J: Treatment and management of graft-versus-host disease: Improving response and survival. Ther Adv Hematol. 4:366–378. 2013. View Article : Google Scholar : PubMed/NCBI
7	Wang Y, Chen X, Cao W and Shi Y: Plasticity of mesenchymal stem cells in immunomodulation: Pathological and therapeutic implications. Nat Immunol. 15:1009–1016. 2014. View Article : Google Scholar : PubMed/NCBI
8	Fajardo-Orduña GR, Mayani H and Montesinos JJ: Hematopoietic support capacity of mesenchymal stem cells: Biology and clinical potential. Arch Med Res. 46:589–596. 2015. View Article : Google Scholar : PubMed/NCBI
9	Dotoli GM, De Santis GC, Orellana MD, de Lima Prata K, Caruso SR, Fernandes TR, Rensi Colturato VA, Kondo AT, Hamerschlak N, Simões BP and Covas DT: Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation. Bone Marrow Transplant. 52:859–862. 2017. View Article : Google Scholar : PubMed/NCBI
10	Muroi K, Miyamura K, Okada M, Yamashita T, Murata M, Ishikawa T, Uike N, Hidaka M, Kobayashi R, Imamura M, et al: Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: A phase II/III study. Int J Hematol. 103:243–250. 2016. View Article : Google Scholar : PubMed/NCBI
11	Cho KA, Park M, Kim YH, Ryu KH and Woo SY: Mesenchymal stem cells inhibit RANK-RANKL interactions between osteoclasts and Th17 cells via osteoprotegerin activity. Oncotarget. 8:83419–83431. 2017. View Article : Google Scholar : PubMed/NCBI
12	Cho KA, Lee JK, Kim YH, Park M, Woo SY and Ryu KH: Mesenchymal stem cells ameliorate B-cell-mediated immune responses and increase IL-10-expressing regulatory B cells in an EBI3-dependent manner. Cell Mol Immunol. Jan 2–2017;(Epub ahead of print).
13	Cho KA, Park M, Kim YH, Woo SY and Ryu KH: Conditioned media from human palatine tonsil mesenchymal stem cells regulates the interaction between myotubes and fibroblasts by IL-1Ra activity. J Cell Mol Med. 21:130–141. 2017. View Article : Google Scholar : PubMed/NCBI
14	Ryu KH, Cho KA, Park HS, Kim JY, Woo SY, Jo I, Choi YH, Park YM, Jung SC, Chung SM, et al: Tonsil-derived mesenchymal stromal cells: Evaluation of biologic, immunologic and genetic factors for successful banking. Cytotherapy. 14:1193–1202. 2012. View Article : Google Scholar : PubMed/NCBI
15	Cantinieaux D, Quertainmont R, Blacher S, Rossi L, Wanet T, Noël A, Brook G, Schoenen J and Franzen R: Conditioned medium from bone marrow-derived mesenchymal stem cells improves recovery after spinal cord injury in rats: An original strategy to avoid cell transplantation. PLoS One. 8:e695152013. View Article : Google Scholar : PubMed/NCBI
16	Gehmert S, Wenzel C, Loibl M, Brockhoff G, Huber M, Krutsch W, Nerlich M, Gosau M, Klein S, Schreml S, et al: Adipose tissue-derived stem cell secreted IGF-1 protects myoblasts from the negative effect of myostatin. Biomed Res Int. 2014:1290482014. View Article : Google Scholar : PubMed/NCBI
17	Sadeghi B, Aghdami N, Hassan Z, Forouzanfar M, Rozell B, Abedi-Valugerdi M and Hassan M: GVHD after chemotherapy conditioning in allogeneic transplanted mice. Bone Marrow Transplant. 42:807–818. 2008. View Article : Google Scholar : PubMed/NCBI
18	Cho KA, Woo SY, Park YS, Park MH and Ryu KH: Macrophage inflammatory protein-2 (MIP-2)/CXCR2 blockade attenuates acute graft-versus-host disease while preserving graft-versus-leukemia activity. Biochem Biophys Res Commun. 426:558–564. 2012. View Article : Google Scholar : PubMed/NCBI
19	Joo SY, Cho KA, Jung YJ, Kim HS, Park SY, Choi YB, Hong KM, Woo SY, Seoh JY and Ryu KH: Bioimaging for the monitoring of the in vivo distribution of infused mesenchymal stem cells in a mouse model of the graft-versus-host reaction. Cell Biol Int. 35:417–421. 2011. View Article : Google Scholar : PubMed/NCBI
20	Joo SY, Cho KA, Jung YJ, Kim HS, Park SY, Choi YB, Hong KM, Woo SY, Seoh JY, Cho SJ and Ryu KH: Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner. Cytotherapy. 12:361–370. 2010. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Dyer DP, Thomson JM, Hermant A, Jowitt TA, Handel TM, Proudfoot AE, Day AJ and Milner CM: TSG-6 inhibits neutrophil migration via direct interaction with the chemokine CXCL8. J Immunol. 192:2177–2185. 2014. View Article : Google Scholar : PubMed/NCBI
23	Dyer DP, Salanga CL, Johns SC, Valdambrini E, Fuster MM, Milner CM, Day AJ and Handel TM: The anti-inflammatory protein TSG-6 regulates chemokine function by inhibiting chemokine/glycosaminoglycan interactions. J Biol Chem. 291:12627–12640. 2016. View Article : Google Scholar : PubMed/NCBI
24	Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, et al: Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 15:804–811. 2009. View Article : Google Scholar : PubMed/NCBI
25	Arima N, Nakamura F, Fukunaga A, Hirata H, Machida H, Kouno S and Ohgushi H: Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: A pilot study. Cytotherapy. 12:265–268. 2010. View Article : Google Scholar : PubMed/NCBI
26	Wysocki CA, Panoskaltsis-Mortari A, Blazar BR and Serody JS: Leukocyte migration and graft-versus-host disease. Blood. 105:4191–4199. 2005. View Article : Google Scholar : PubMed/NCBI
27	Kim JY, Park M, Kim YH, Ryu KH, Lee KH, Cho KA and Woo SY: Tonsil-derived mesenchymal stem cells (T-MSCs) prevent Th17-mediated autoimmune response via regulation of the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway. J Tissue Eng Regen Med. 12:e1022–e1033. 2018. View Article : Google Scholar : PubMed/NCBI